The Fly

Clover Health price target lowered to $4 from $7 at Canaccord

Canaccord analyst Richard Close lowered the firm’s price target on Clover Health to $4 from $7 and keeps a Buy rating on the shares. The analyst said the company’s results outperformed his estimates in 3Q and raised its 2022 guidance. He said the biggest development exiting 3Q is management’s increased focus on its timeline to profitability and decision to moderate growth in both its MA and non-insurance offerings, which causes him to lower his revenue estimates, but should shorten Clover’s timeline to profitability.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CLOV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More